ReviewBiosensors2026
Biosensor-Integrated Microneedle Devices for Diagnosis and Treatment of Chronic and Infectious Diseases: Current Status, Trends and Challenges.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite advancements in clinical diagnostics, traditional biomarker detection methods (e.g., ELISA) remain limited due to their invasive nature, slow results, and inadequate use for continuous monitoring in low-resource settings. With the rise in chronic, infectious, and metabolic diseases, there is a pressing demand for real-time, minimally invasive diagnostic tools. Nanoengineered microneedle (MN) biosensors offer a promising solution. These painless devices can access interstitial fluid (ISF), a rich source of biomarkers, while utilizing advanced nanomaterials for high sensitivity and multiplexed detection. When combined with AI, IoT connectivity, and cloud-based analytics, MN biosensors enable personalized health data and continuous disease management. This review outlines recent advances in MN technology, including innovations in design and nanomaterial integration, as well as translational challenges like manufacturing scalability and regulatory approval. We explore how MN designs incorporating various sensing modalities can facilitate real-time monitoring of biomarkers such as glucose, lactate, and inflammatory proteins. Importantly, we discuss how these devices can improve healthcare access, reduce costs, and empower patients through everyday monitoring. This review integrates developments in MN engineering with biosensing and therapeutics, positioning biosensor-integrated MNs as pivotal in enabling continuous, minimally invasive disease monitoring and personalized therapy beyond traditional hospital environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.